Spotlight On... Seqirus to build new U.K. manufacturing outpost; GSK scouts for new CEO; GeoVax to collaborate with U.S. Army research institute; and more...

Seqirus--the world's second largest flu vaccine player formed from CSL's purchase of Novartis' ($NVS) flu vaccines--is expanding in the U.K. It'll spend £15.3 million ($21.3 million) on a new flu vaccine manufacturing site in Speke, an announcement the company made as it opened a £6.8 million warehouse there. The company is the second largest flu vaccine player, behind Sanofi ($SNY), with more than 2,000 employees worldwide. More from FiercePharmaManufacturing

> GlaxoSmithKline ($GSK) is starting a search for a new CEO. Story

> GeoVax announced plans to work with the United States Army Medical Research Institute of Infectious Diseases on a vaccine effort against hemorrhagic fever viruses. Release

> Researchers at Oxford University have begun a clinical trial of a prostate cancer vaccine candidate, aiming to vaccinate 48 men with low or intermediate prostate cancer risk to test safety and immune responses. Release

> A team led by University of Exeter in the U.K. has developed a vaccine with the potential to protect from melioidosis, or Whitmore's disease, an often fatal disease in tropical regions. Release

Suggested Articles

After countless headlines from a Dengvaxia safety scandal in the Philippines, officials are now considering using the Sanofi vaccine again.

Merck's oncology superstar Keytruda has been stealing the spotlight, but in vaccines, the drugmaker has growth figures to tout.

Experts are pushing for the introduction of J&J's vaccine in the response to the Ebola outbreak in the Democratic Republic of Congo.